723 related articles for article (PubMed ID: 14531725)
21. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Gerber JG; Rosenkranz SL; Fichtenbaum CJ; Vega JM; Yang A; Alston BL; Brobst SW; Segal Y; Aberg JA;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):307-12. PubMed ID: 15980690
[TBL] [Abstract][Full Text] [Related]
22. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U
Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
[TBL] [Abstract][Full Text] [Related]
23. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
Meena AK; Ratnam DV; Chandraiah G; Ankola DD; Rao PR; Kumar MN
Lipids; 2008 Mar; 43(3):231-41. PubMed ID: 18196308
[TBL] [Abstract][Full Text] [Related]
24. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
Derks M; Abt M; Parr G; Meneses-Lorente G; Young AM; Phelan M
Expert Opin Investig Drugs; 2010 Oct; 19(10):1135-45. PubMed ID: 20738227
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Miller DB; Spence JD
Clin Pharmacokinet; 1998 Feb; 34(2):155-62. PubMed ID: 9515185
[TBL] [Abstract][Full Text] [Related]
26. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
Malinowski JM
Am J Health Syst Pharm; 1998 Nov; 55(21):2253-67; quiz 2302-3. PubMed ID: 9825877
[TBL] [Abstract][Full Text] [Related]
27. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.
Narwal R; Akhlaghi F; Asberg A; Hermann M; Rosenbaum SE
Clin Pharmacokinet; 2010 Oct; 49(10):693-702. PubMed ID: 20818835
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
[TBL] [Abstract][Full Text] [Related]
29. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
30. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
[TBL] [Abstract][Full Text] [Related]
31. Erythromycin coadministration increases plasma atorvastatin concentrations.
Siedlik PH; Olson SC; Yang BB; Stern RH
J Clin Pharmacol; 1999 May; 39(5):501-4. PubMed ID: 10234598
[TBL] [Abstract][Full Text] [Related]
32. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
33. Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics.
Date AA; Nagarsenker MS
J Pharm Pharmacol; 2007 Nov; 59(11):1583-4. PubMed ID: 17976271
[No Abstract] [Full Text] [Related]
34. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Shin J; Pauly DF; Pacanowski MA; Langaee T; Frye RF; Johnson JA
Pharmacotherapy; 2011 Oct; 31(10):942-50. PubMed ID: 21950641
[TBL] [Abstract][Full Text] [Related]
35. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
36. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Whitfield LR; Porcari AR; Alvey C; Abel R; Bullen W; Hartman D
J Clin Pharmacol; 2011 Mar; 51(3):378-88. PubMed ID: 20413454
[TBL] [Abstract][Full Text] [Related]
37. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
Hermann M; Bogsrud MP; Molden E; Asberg A; Mohebi BU; Ose L; Retterstøl K
Clin Pharmacol Ther; 2006 Jun; 79(6):532-9. PubMed ID: 16765141
[TBL] [Abstract][Full Text] [Related]
38. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Boyd RA; Stern RH; Stewart BH; Wu X; Reyner EL; Zegarac EA; Randinitis EJ; Whitfield L
J Clin Pharmacol; 2000 Jan; 40(1):91-8. PubMed ID: 10631627
[TBL] [Abstract][Full Text] [Related]
39. Interaction between several medicines and statins.
Fujino H; Saito T; Tsunenari Y; Kojima J
Arzneimittelforschung; 2003; 53(3):145-53. PubMed ID: 12705168
[TBL] [Abstract][Full Text] [Related]
40. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
